Norfolk & Norwich University Hospital, Norwich, UK.
Pediatr Crit Care Med. 2011 Nov;12(6):e407-9. doi: 10.1097/PCC.0b013e3181fe449f.
Intracardiac thrombosis is a life-threatening complication of extreme prematurity. We describe the use of tissue plasminogen activator to treat intracardiac thrombosis in extremely low-birth-weight preterm infants.
Case series, literature review, and practice guideline for recombinant tissue plasminogen activator treatment of intracardiac thrombosis in extremely low-birth-weight preterm infants.
Neonatal intensive care.
Four extremely low-birth-weight preterm infants coincidentally diagnosed with intracardiac thrombosis during neonatal intensive care.
Recombinant tissue plasminogen activator in a starting dose of 20 μg/kg/hr, increasing to 200-400 μg/kg/hr, infused for 2-6 days.
Thrombolytic therapy with recombinant tissue plasminogen activator helped achieve rapid clot resolution in all infants and none had any major hemorrhagic complication associated with treatment.
Tissue plasminogen activator may safely be used to treat intracardiac thrombosis in extremely low-birth-weight preterm infants. Close monitoring of therapy is imperative. Further data are required to confirm the safety of tissue plasminogen activator in preterm infants.
心内血栓形成是极早产儿的一种危及生命的并发症。我们描述了使用组织型纤溶酶原激活物治疗极低出生体重早产儿的心内血栓形成。
病例系列、文献复习和重组组织型纤溶酶原激活物治疗极低出生体重早产儿心内血栓形成的临床实践指南。
新生儿重症监护病房。
4 名极低出生体重早产儿在新生儿重症监护期间偶然被诊断为心内血栓形成。
重组组织型纤溶酶原激活物起始剂量为 20μg/kg/hr，增加至 200-400μg/kg/hr，输注 2-6 天。
重组组织型纤溶酶原激活物溶栓治疗使所有婴儿迅速溶解血栓，且无任何与治疗相关的严重出血并发症。
组织型纤溶酶原激活物可安全用于治疗极低出生体重早产儿的心内血栓形成。必须密切监测治疗。需要进一步的数据来确认组织型纤溶酶原激活物在早产儿中的安全性。
